Corvel Corp (CRVL) · Nov 2, 2026 · Earnings
Beat — EPS $0.67 vs available estimate ~$0.62; revenue $267.1M vs ~$268M
CorVel’s earnings show 11% revenue growth, 24% EPS growth, expanding margins and fresh CERIS payer traction—without formal guidance changes.
CorVel is a debt-free claims-management and healthcare-cost platform moving from its traditional workers’ compensation base toward a more technology-led model, using AI, automation and CERIS payment-integrity services to expand within insurers and healthcare payers. Its fiscal 2027 setup already featured strong growth, AI investment and CERIS expansion, so this quarter confirms that strategy is producing operating results rather than introducing a wholly new direction.
The quarter was a modest earnings beat, not a revenue surprise. Revenue grew 11% to $267.1 million, essentially matching the available pre-release estimate of about $268 million, while diluted EPS of $0.67 exceeded the available estimate of about $0.62. There is no published analyst consensus for CorVel, so the comparison is against an external desk estimate rather than a formal consensus.
| Q2 FY2027 | Q2 FY2026 | Available estimate | |
|---|---|---|---|
| Revenue (Income Statement) | $267.1M (+11%) | $239.6M | $268M |
| Gross profit (Income Statement) | $72.3M (+24%) | $58.2M | |
| Gross margin (Highlights) | 27% | 24% | |
| Diluted EPS (Income Statement) | $0.67 (+24%) | $0.54 | $0.62 |
| Cash (Condensed Balance Sheet) | $270.0M |
The best part of the release is the margin conversion. Gross profit rose 24%, more than twice the pace of revenue, lifting gross margin to 27% from roughly 24% a year earlier. That suggests CorVel is gaining operating leverage from its claims technology, customer mix or managed-care offerings, rather than merely adding volume.
CERIS is becoming a more credible growth engine, but the release still gives no revenue split. CorVel says CERIS implemented another Top 10 national health plan and secured a partnership giving it access to the Blue Cross Blue Shield market, while adding hospital-bill-audit and professional-claims products. Those are meaningful distribution and product milestones for the payment-integrity strategy, but the filing does not quantify their revenue contribution or establish how quickly they will scale. 〔0〕
The balance sheet preserves flexibility while buybacks continue. CorVel exited with approximately $270 million of cash, no borrowings and $18.1 million of quarterly repurchases, while diluted shares fell to 50.7 million from 51.7 million year over year. This supports per-share growth, but it is a capital-allocation reinforcement of the existing model—not a new strategic catalyst.
Bottom line: This was a healthy execution quarter: revenue was roughly in line with the available expectation, but profitability and gross margin came in better, with CERIS adding tangible commercial traction. It strengthens CorVel’s existing growth-and-automation story without rewriting it.
Q3 FY2027 earnings report, expected February 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!